Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Skye Bioscience combines with Redx Pharma in a Nasdaq deal backed by $125M financing. The merger will create Fibrx Therapeutics and fund operations into 2029.
PUBLIC · SKYEAug 14, 2026•1 day ago
Amount Raised
$125 Million
Round Type
Series A
San DiegoBiotechnologyHealthcareDescription
Skye Bioscience and Redx Pharma have reached a deal to merge, forming Fibrx Therapeutics. The transaction includes approximately $125 million in financings, which will help fund new developments. Existing shareholders from both companies will hold significant ownership in the new entity. The financing will support operations and clinical studies through 2029.
Don't miss Skye Bioscience's next move
Get an email the moment Skye Bioscience raises, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contactVerified contactsPunit D., Chief Executive Officer & Director
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech